Definium Therapeutics, Inc.
No SEC Form 4 filings for $DFTX in the last 30 days.
See all $DFTX insider activity →Definium Therapeutics (Nasdaq: DFTX) shares rose up to 18% after the company reported positive top-line results from Voyage, its first Phase III study of DT120 (lysergide) ODT 100 µg for adults with generalized anxiety disorder. The readout follows earlier positive Phase III results for DT120 in major depressive disorder reported in June.
Definium Therapeutics (NASDAQ:DFTX) reported DT120 met Phase III goals in a GAD study. At week 1, HAM-A improved 11.9 points from baseline, 7.7 placebo-adjusted, with p<0.0001 at all time points. At week 12, remission was 14% vs 4% placebo; response 43% vs 16%. DT120 was generally well tolerated; no serious AEs or deaths in DT120.
Definium Therapeutics (Nasdaq: DFTX) reported positive topline Phase 3 Voyage results for DT120 (lysergide) ODT 100 µg in adults with generalized anxiety disorder. The study met primary and key secondary endpoints, with HAM-A Week 12 placebo-adjusted change of 5.4 points (p<0.0001). DT120 was generally well tolerated; no new safety signals. Webcast scheduled for 8:00 am EDT.
Over the past 7 days, alphai's AI scored 4 news stories mentioning DFTX (Definium Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent DFTX coverage spans earnings, technology and financial news.
Positive Phase III top-line readout for DT120 in GAD is a meaningful de-risking event and likely increases probability of eventual regulatory approval.
Positive Phase III efficacy and safety signals for DT120 ODT in GAD, plus extension durability and FDA filing discussions, can re-rate clinical and regulatory odds.
Positive Phase 3 readout in a pivotal GAD program increases probability of regulatory success and can re-rate late-stage biotech risk, especially with a second Phase 3 win.
Positive Phase 3 readout for DT120 ODT in GAD increases probability of regulatory and commercial upside, likely supporting near-term momentum and risk-on positioning.
Call highlights increase conviction around DT120 pivotal readiness and near-term catalysts, while financing and warrant revaluation add volatility risk.
alphai scores every news story that mentions DFTX with an AI model for sentiment and relevance, and aggregates insider trades from Definium Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Definium Therapeutics (Nasdaq: DFTX) shares rose up to 18% after the company reported positive top-line results from Voyage, its first Phase III study of DT120 (lysergide) ODT 100 µg for adults with generalized anxiety disorder. The readout follows earlier positive Phase III results for DT120 in major depressive disorder reported in June.
2 min readDefinium Therapeutics (NASDAQ:DFTX) reported DT120 met Phase III goals in a GAD study. At week 1, HAM-A improved 11.9 points from baseline, 7.7 placebo-adjusted, with p<0.0001 at all time points. At week 12, remission was 14% vs 4% placebo; response 43% vs 16%. DT120 was generally well tolerated; no serious AEs or deaths in DT120.
6 min readDefinium Therapeutics (Nasdaq: DFTX) reported positive topline Phase 3 Voyage results for DT120 (lysergide) ODT 100 µg in adults with generalized anxiety disorder. The study met primary and key secondary endpoints, with HAM-A Week 12 placebo-adjusted change of 5.4 points (p<0.0001). DT120 was generally well tolerated; no new safety signals. Webcast scheduled for 8:00 am EDT.
6 min readDefinium Therapeutics (NASDAQ:DFTX) shares rose about 20% premarket after positive topline Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder. The study met its primary endpoint and key secondary endpoints, with placebo-adjusted HAM-A reduction of 5.4 points at Week 12 (p<0.0001). Safety was generally mild to moderate with no new signals.
4 min readDefinium Therapeutics (NASDAQ:DFTX) reported Q2 results and discussed Phase II GAD data for DT120, saying efficacy was seen by week one and remained significant through week 12, with improvements on secondary endpoints and favorable tolerability. It said VOYAGE and PANORAMA were re-estimated to exceed 99% power. Net loss was $159M, including $86.2M non-cash warrant fair-value expense. The company raised about $758M net in June and had about $1.1B cash to fund operations into 2030.
7 min readDefinium Therapeutics (NASDAQ: DFTX) reported Q2 2026 results and Phase 3 updates for DT120 ODT. It said Phase 3 Emerge in major depressive disorder met primary and key secondary endpoints, with placebo-adjusted MADRS improvements of 8.1 points at Week 6 and 7.3 at Week 12. Voyage and Panorama topline data are expected Aug 10 and Sept 2026. Cash, cash equivalents and investments were about $1.1B as of June 30, 2026, after a $805M gross public offering.
6 min readDefinium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dftx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robu
7 min readMeridian Small Cap Growth Fund’s Q2 2026 investor letter, managed by ArrowMark Partners, reported a 21.54% return for the quarter ended June 30, 2026, versus 25.71% for the Russell 2000 Growth Index. The letter highlighted Definium Therapeutics (NASDAQ:DFTX), noting its Phase 3 major depressive disorder topline results and a share price of $42.16 on July 29, 2026.
3 min readPwC estimates over $300 billion in branded pharma revenue will lose patent exclusivity by decade end, driving large drugmakers to buy pipelines. ALPS Advisors says biopharma deal value could exceed $250B in 2026. The ALPS Medical Breakthroughs ETF (SBIO) added 37 names in June; it holds ABBV’s $10.9B Apogee deal target APGE and Definium (DFTX).
7 min readThe article says the AdvisorShares Psychedelics ETF rose 31% over the past year, outpacing the Nasdaq and S&P 500. It cites optimism from Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary and notes J&J’s Spravato sales exceeded $1B in 2024, projected to reach $3B by 2027-28. It lists analyst-favored psychedelic stocks, including Definium Therapeutics (DFTX) and COMPASS Pathways (CMPS), with stated price-target upside of 28.15% and 38.57%.
7 min read
